EirGenix Inc. (TPE:6589)

Market Cap	22.73B
Revenue (ttm)	936.18M
Net Income (ttm)	-705.76M
Shares Out	302.20M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	550,272
Average Volume	1,638,426
Open	75.10
Previous Close	74.50
Day's Range	73.90 - 76.20
52-Week Range	52.70 - 96.10
Beta	0.58
RSI	54.46
Earnings Date	Nov 12, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 207
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6589

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.